ArticleTranslational lung cancer research2022
Clinical features and prognosis of resectable pulmonary primary invasive mucinous adenocarcinoma.
Article in Translational lung cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Prognostic factors for resected invasive mucinous lung adenocarcinoma: a systematic review and meta-analysis.BMC cancer · 2024Pooled it
- Radiomics nomogram for preoperative differentiation of pulmonary mucinous adenocarcinoma from tuberculoma in solitary pulmonary solid nodules.BMC cancer · 2023Trial
- Clinicoradiologic features and evolutionary characteristics of pulmonary focal mucinous adenocarcinomas across different density patterns: a retrospective multi-center study.Quantitative imaging in medicine and surgery · 2026Article
- A retrospective cohort study integrating invasive mucinous adenocarcinoma into the IASLC grading system for lung adenocarcinoma.Translational lung cancer research · 2026Article
- The Heterogeneity of Mucinous Colorectal Adenocarcinoma-Histologic and Molecular Phenotypes Drive Prognostic Outcomes.Cancers · 2026Article
- Molecular characteristics, clonal relatedness and surgical outcomes of pulmonary mixed invasive mucinous and non-mucinous adenocarcinoma: a retrospective cohort study.Molecular biomedicine · 2026Article
- Critical role of spread through air spaces in prognosis of stage IA3 non-small cell lung cancer: insights from a real-world multicenter study.Journal of thoracic disease · 2025Article
- The prognostic impact of body mass index on patients with gastric adenocarcinoma and mucinous adenocarcinoma: a retrospective cohort study.Journal of gastrointestinal oncology · 2025Article
- Kartagener Syndrome Complicated by Middle and Lower Lobar Mucinous Adenocarcinoma in the Left Lung.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2025Article
- Nomogram predicting overall and cancer specific prognosis for poorly differentiated lung adenocarcinoma after resection based on SEER cohort analysis.Scientific reports · 2024Article
- Nomogram model for the diagnosis of solitary nodular pulmonary mucinous adenocarcinoma.Scientific reports · 2024Article
- Radiological Features of Primary Pulmonary Invasive Mucinous Adenocarcinoma Based on 312 Consecutive Patients.The clinical respiratory journal · 2024Article
- Pathological and imaging features of pulmonary invasive mucinous adenocarcinoma-a retrospective cohort study.Translational lung cancer research · 2024Article
- Pulmonary mucinous adenocarcinoma: An overview of pathophysiology and advancements in treatment.Heliyon · 2024Review
- Article
- Radiological and clinical features of large consolidative-type pulmonary invasive mucinous adenocarcinoma.The clinical respiratory journal · 2024Article
- Construction and validation of a prognostic signature for mucinous colonic adenocarcinoma based on N7-methylguanosine-related long non-coding RNAs.Journal of gastrointestinal oncology · 2024Article
- Invasive mucinous adenocarcinoma misdiagnosed as pneumonia: A case report.Experimental and therapeutic medicine · 2023Article
- Postoperative survival of pulmonary invasive mucinous adenocarcinoma versus non-mucinous invasive adenocarcinoma.BMC pulmonary medicine · 2023Article
- Erratum to clinical features and prognosis of resectable pulmonary primary invasive mucinous adenocarcinoma.Translational lung cancer research · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: According to the latest the World Health Organization (WHO) classification in 2015, invasive mucinous adenocarcinoma (IMA) is defined as a new pathological subtype of lung adenocarcinoma (LUAD). However, whether this rare subtype of lung pathology has any difference in prognosis than conventional LUAD is debatable. Our study attempted to compare clinical characteristics and prognosis of IMA Methods: A total of 1,857 patients with LUAD who underwent radical resection were screened from 2010 to 2015 at Zhejiang Cancer Hospital. Patients with pulmonary IMA were matched 1:1 by using propensity scores with LUAD adjusted for clinicopathological characteristics. After follow-up, overall survival (OS) and disease-free survival (DFS) were explored by Kaplan-Meier and Cox regression analyses. Forest plots were used for subgroup analyses. Results: Following screening, 499 patients with LUAD were enrolled, with 97 IMA and 402 NMA. Compared to NMA of the lung, IMA was proportionately lower in women (50.5% Conclusions: In this study, we found that resectable IMA patients had a better OS than NMA patients. This study contributes to the understanding of IMA in depth, but it needs to be validated through additional multicenter studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.